A randomized phase III trial of gemcitabine + docetaxel + bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma (uLMS): a Gynecologic Oncology Group study

Hensley, Martee

2 - Scientific Plenary
A randomized phase III trial of gemcitabine + docetaxel + bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma (uLMS): a Gynecologic Oncology Group study

Saturday, March 22, 2014: 8:36 AM

Ballroom B/C (Tampa Convention Center)

M. L. Hensley¹, A. Miller², D. M. O'Malley³, R. S. Mannel⁴, K. Behbakht⁵, J. N. Bakkum-Gamez⁶ and H. Michael⁷
¹Memorial Sloan-Kettering Cancer Center, New York, NY, ²Gynecologic Oncology Group, Buffalo, NY, ³The Ohio State University, Columbus, OH, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵University of Colorado Denver, Aurora, CO, ⁶Mayo Clinic, Rochester, MN, ⁷Indiana University School of Medicine, Indianapolis, IN

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

2 - Scientific Plenary
A randomized phase III trial of gemcitabine + docetaxel + bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma (uLMS): a Gynecologic Oncology Group study

2 - Scientific Plenary A randomized phase III trial of gemcitabine + docetaxel + bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma (uLMS): a Gynecologic Oncology Group study

2 - Scientific Plenary
A randomized phase III trial of gemcitabine + docetaxel + bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma (uLMS): a Gynecologic Oncology Group study